7/30/2019 8:04:00 AM
Ligand Pharma Q2 Loss Per Share $0.74 Vs Profit $2.99 Last Year
7/23/2019 4:35:39 PM
Ligand Pharmaceuticals Acquires Ab Initio Biotherapeutics
7/10/2019 9:05:07 AM
Ligand Report Positive Top Line Results From Phase 1 Trial Of CE Iohexol Program
7/8/2019 8:32:14 AM
Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol License And Supply Deals For Furosemide Formulation
3/21/2019 9:10:04 AM
Ligand To Receive $3 Mln Milestone Payment As Result Of FDA Approval Of Sage Therapeutics’ ZULRESSOTM Injection
2/7/2019 5:14:03 PM
Ligand Pharma Q4 Loss/share $2.02 Vs. Loss $0.33 Year Ago
2/7/2019 9:00:35 AM
Ligand Pharmaceuticals Enters Worldwide OmniAb Partnership With Genagon Therapeutics AB
2/4/2019 4:12:23 PM
Ligand Announces Closing Investment In Dianomi Therapeutics
1/25/2019 9:02:35 AM
Ligand Partner Seelos Therapeutics Becomes Public Company
1/24/2019 8:05:01 AM
Seelos Therapeutics Completes Merger With Apricus Biosciences
1/16/2019 4:35:59 PM
Rev. Fr. Emmanuel Lemelson Renews Calls For An Investigation In Ligand
12/18/2018 5:14:54 PM
Ligand Pharmaceuticals Inc (LGND) Has Raised Its 2018 Revenue Estimate To $244 Mln From $240 Mln
12/18/2018 5:05:28 PM
Ligand Pharmaceuticals Raises FY18 Outook; Now Expects Revenues Of Approx. $244 Mln And Adj. EPS Of Approx. $6.63
12/17/2018 4:02:21 PM
Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics
12/10/2018 10:03:02 AM
Sermonix Announces FDA Acceptance Of IND Application On Phase 2 Trial Of Lasofoxifene